Filana Therapeutics, Inc.
FLNA
$1.91
-$0.09-4.50%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 26.59M | 43.27M | 56.99M | 67.07M | 69.64M |
| Gross Profit | -26.59M | -43.27M | -56.99M | -67.07M | -69.64M |
| SG&A Expenses | 30.50M | 33.76M | 39.90M | 82.93M | 81.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.09M | 77.03M | 96.89M | 150.00M | 151.35M |
| Operating Income | -57.09M | -77.03M | -96.89M | -150.00M | -151.35M |
| Income Before Tax | -90.97M | -106.03M | -123.17M | -72.79M | -24.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -90.97 | -106.03 | -123.17 | -72.79 | -24.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.97M | -106.03M | -123.17M | -72.79M | -24.34M |
| EBIT | -57.09M | -77.03M | -96.89M | -150.00M | -151.35M |
| EBITDA | -56.15M | -76.20M | -95.93M | -148.96M | -150.21M |
| EPS Basic | -1.88 | -2.20 | -2.56 | -1.51 | -0.44 |
| Normalized Basic EPS | -0.68 | -0.93 | -1.17 | -1.00 | -0.41 |
| EPS Diluted | -1.89 | -2.20 | -2.56 | -1.51 | -1.45 |
| Normalized Diluted EPS | -0.68 | -0.93 | -1.17 | -1.00 | -0.42 |
| Average Basic Shares Outstanding | 193.19M | 192.98M | 192.65M | 190.54M | 185.28M |
| Average Diluted Shares Outstanding | 193.19M | 192.98M | 192.65M | 190.54M | 186.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |